Research Progress on Amino Acid Metabolism in Head and Neck Squamous Cell Carcinoma

doi:10.13701/j.cnki.kqyxyj.2026.09.002

Abstract

Abstract: Head and neck squamous cell carcinoma (HNSCC) is the sixth most common malignant tumor worldwide, characterized by high invasiveness, easy metastasis, and poor prognosis. Tumor cell metabolic reprogramming is one of the key features in the occurrence and development of HNSCC. Among them, amino acid metabolic reprogramming, as an important source of nutrition and energy for tumor cells, plays a crucial role in promoting the rapid proliferation of HNSCC tumor cells and adapting to the tumor microenvironment. This review aims to systematically elaborate on the research progress of amino acid metabolic reprogramming in HNSCC, focusing on its potential value and application prospects in early diagnosis, targeted treatment, and prognosis assessment of the disease, with the aim of providing effective strategies to improve the survival quality and prolong the survival period of HNSCC patients.

Key words: head and neck squamous cell carcinoma, metabolic reprogramming, amino acid metabolism, biological markers

TAN Xiao, YANG Xihu. Research Progress on Amino Acid Metabolism in Head and Neck Squamous Cell Carcinoma[J]. Journal of Oral Science Research, 2026, 42(9): 740-745.

References

[1] Cao H, Lan T, Kuang S, et al. FAT1 as a tumor mutation burden specific gene affects the immunotherapy effect in head and neck squamous cell cancer [J]. Drug Resist Updat, 2024, 76:101095.
[2] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[3] Thakral A, Lee JJ, Hou T, et al. Smoking and alcohol by HPV status in head and neck cancer: a Mendelian randomization study [J]. Nat Commun, 2024, 15(1):7835.
[4] Yu VX, Long S, Tassler A. Smoking and head and neck cancer [J]. JAMA Otolaryngol Head Neck Surg, 2023, 149(5):470.
[5] Zhang Y, Li Z, Zhang C, et al. Recent advances of photodiagnosis and treatment for head and neck squamous cell carcinoma [J]. Neoplasia, 2025, 60:101118.
[6] Guo Z, Li K, Ren X, et al. The role of the tumor microenvironment in HNSCC resistance and targeted therapy [J]. Front Immunol, 2025, 16:1554835.
[7] He L, Wan M, Yang X, et al. Distant metastasis of oral squamous cell carcinoma: immune escape mechanism and new perspectives on treatment [J]. Discov Oncol, 2025, 16(1): 257.
[8] Kohli M, Poulogiannis G. Harnessing the power of metabolomics for precision oncology: current advances and future directions [J]. Cells, 2025, 14(6):402.
[9] Najumudeen AK, Ceteci F, Fey SK, et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer [J]. Nat Genet, 2021, 53(1): 16-26.
[10] Zhang XY, Shi JB, Jin SF, et al. Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape [J]. Cancer Commun (Lond), 2024, 44(6): 670-694.
[11] Yang XH, Jing Y, Wang S, et al. Integrated non-targeted and targeted metabolomics uncovers amino acid markers of oral squamous cell carcinoma [J]. Front Oncol, 2020, 10: 426.
[12] Ohashi T, Terazawa K, Shibata H, et al. Metabolic profiling analysis of head and neck squamous cell carcinoma [J]. Oral Dis, 2024, 30(2): 342-352.
[13] Lohavanichbutr P, Zhang Y, Wang P, et al. Salivary metabolite profiling distinguishes patients with oral cavity squamous cell carcinoma from normal controls [J]. PLoS One, 2018, 13: e0204249.
[14] Ferrari E, Antonelli R, Gallo M, et al. Salivary metabolomics discloses metabolite signatures of oral leukoplakia with and without dysplasia [J]. Int J Mol Sci, 2025, 26(13): 6519.
[15] Vsiansky V, Svobodova M, Gumulec J, et al. Prognostic significance of serum free amino acids in head and neck cancers [J]. Cells, 2019, 8(5): 428.
[16] Li S, Zeng H, Fan J, et al. Glutamine metabolism in breast cancer and possible therapeutic targets [J]. Biochem Pharmacol, 2023, 210:115464.
[17] Stine ZE, Schug ZT, Salvino JM, et al. Targeting cancer metabolism in the era of precision oncology [J]. Nat Rev Drug Discov, 2022, 21(2): 141-162.
[18] Jin J, Byun JK, Choi YK, et al. Targeting glutamine metabolism as a therapeutic strategy for cancer [J]. Exp Mol Med, 2023, 55(4):706-715.
[19] Bodineau C, Tomé M, Murdoch PDS, et al. Glutamine, mTOR and autophagy: a multiconnection relationship [J]. Autophagy, 2022, 18(11):2749-2750.
[20] Wang D, Duan JJ, Guo YF, et al. Targeting the glutamine-arginine-proline metabolism axis in cancer [J]. J Enzyme Inhib Med Chem, 2024, 39(1):2367129.
[21] Zhang Z, Liu R, Shuai Y, et al. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma [J]. Br J Cancer, 2020, 122(1): 82-93.
[22] Chen XY, Chen X, Liang XH, et al. Yuanhuacine suppresses head and neck cancer growth by promoting ASCT2 degradation and inhibiting glutamine uptake [J]. Acta Pharmacol Sin, 2025, 46(10): 2779-2792.
[23] Li X, Peng X, Li Y, et al. Glutamine addiction in tumor cell: oncogene regulation and clinical treatment [J]. Cell Commun Signal, 2024, 22(1):12.
[24] Yang J, Chen F, Lang L, et al. Therapeutic targeting of the GLS1-c-Myc positive feedback loop suppresses glutaminolysis and inhibits progression of head and neck cancer [J]. Cancer Res, 2024, 84(19): 3223-3234.
[25] Qian L, Li N, Lu XC, et al. Enhanced BCAT1 activity and BCAA metabolism promotes RhoC activity in cancer progression [J]. Nat Metab, 2023, 5(7):1159-1173.
[26] Lin Y, Kong JL, Zhu ZY, et al. Research advances in metabolic profiling and imaging markers of invasive front of OSCC [J]. J Oral Maxillofac Surg, 2025, 35(5): 331-342.
[27] Wang L, Yang R, Kong Y, et al. Integrative single-cell and bulk transcriptomes analyses reveals heterogeneity of serine-glycine-one-carbon metabolism with distinct prognoses and therapeutic vulnerabilities in HNSCC [J]. Int J Oral Sci, 2024, 16(1):44.
[28] Liu S, Zhang W, Liu W, et al. PRMT1-mediated SWI/SNF complex recruitment via SMARCC1 drives IGF2BP2 transcription to enhance carboplatin resistance in head and neck squamous cell carcinoma [J]. Adv Sci (Weinh), 2025, 12(22):e2417460.
[29] Li M, Jin S, Zhang Z, et al. Interleukin-6 facilitates tumor progression by inducing ferroptosis resistance in head and neck squamous cell carcinoma [J]. Cancer Lett, 2022, 527:28-40.
[30] Yadav R, Bansal V, Singh A, et al. Metabolomics-based predictive biomarkers of oral cancer and its severity in human patients from North India using saliva [J]. Mol Omics, 2025, 21(4):270-281.
[31] Mohd Faizal NF, Vincent-Chong VK, Ramanathan A, et al. Metabolomic profiling of oral potentially malignant disorders and its clinical values [J]. Biomedicines, 2024, 12(12): 2899.
[32] Li X, Li D, Li J, et al. A prognostic model of head and neck cancer based on amino acid metabolism-related signature and its implication for immunosuppressive microenvironment [J]. Int J Mol Sci, 2023, 24(14): 11753.
[33] Cadoni G, Giraldi L, Chiarla C, et al. Prognostic role of serum amino acids in head and neck cancer [J]. Dis Markers, 2020, 2020: 2291759.
[34] Chen J, Cui L, Lu S, et al. Amino acid metabolism in tumor biology and therapy [J]. Cell Death Dis, 2024, 15(1):42.
[35] Scarini JF, Lavareze L, de Lima-Souza RA, et al. Head and neck squamous cell carcinoma: Exploring frontiers of combinatorial approaches with tyrosine kinase inhibitors and immune checkpoint therapy [J]. Crit Rev Oncol Hematol, 2022, 180:103863.
[36] Allevato MM, Trinh S, Koshizuka K, et al. A genome-wide CRISPR screen reveals that antagonism of glutamine metabolism sensitizes head and neck squamous cell carcinoma to ferroptotic cell death [J]. Cancer Lett, 2024, 598: 217089.
[37] Song A, Wu L, Zhang BX, et al. Glutamine inhibition combined with CD47 blockade enhances radiotherapy-induced ferroptosis in head and neck squamous cell carcinoma [J]. Cancer Lett, 2024, 588: 216727.
[38] Lin X, Zhou W, Liu Z, et al. Targeting cellular metabolism in head and neck cancer precision medicine era: A promising strategy to overcome therapy resistance [J]. Oral Dis, 2023, 29(8): 3101-3120.